Holen Sie sich die Stockscreener-App
1.69
9.74%
0.15
Schlusskurs vom Vortag:
$1.54
Offen:
$1.54
24-Stunden-Volumen:
1.76M
Relative Volume:
1.47
Marktkapitalisierung:
$100.50M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-73.79M
KGV:
-0.5951
EPS:
-2.84
Netto-Cashflow:
$-77.44M
1W Leistung:
+4.32%
1M Leistung:
-55.76%
6M Leistung:
-50.00%
1J Leistung:
-2.87%
1-Tages-Spanne:
$1.51
$1.695
1-Wochen-Bereich:
$1.49
$1.71
52-Wochen-Spanne:
$1.49
$6.85
Pyxis Oncology Inc Stock (PYXS) Company Profile
Firmenname
Pyxis Oncology Inc
Sektor
Branche
Telefon
(617) 221-9059
Adresse
321 HARRISON AVENUE, BOSTON
Vergleichen Sie PYXS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PYXS
Pyxis Oncology Inc
|
1.69 | 100.50M | 0 | -73.79M | -77.44M | -1.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-21 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-11-08 | Eingeleitet | Stephens | Overweight |
| 2024-08-08 | Eingeleitet | Stifel | Buy |
| 2024-05-07 | Fortgesetzt | Jefferies | Buy |
| 2024-02-09 | Eingeleitet | BTIG Research | Buy |
| 2024-01-23 | Eingeleitet | Leerink Partners | Outperform |
| 2023-09-05 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-11-02 | Eingeleitet | BofA Securities | Neutral |
| 2021-11-02 | Eingeleitet | Credit Suisse | Outperform |
| 2021-11-02 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Pyxis Oncology Inc Aktie (PYXS) Neueste Nachrichten
Pyxis Oncology price target lowered to $8 from $10 at RBC Capital - Yahoo Finance
Pyxis Oncology shares target cut, outperform rating on pipeline update By Investing.com - Investing.com Australia
Pyxis Oncology shares target cut, outperform rating on pipeline update - Investing.com
Pyxis Oncology's (PYXS) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Pyxis Oncology's Deprioritizes Second Pipeline Asset, Analyst Applauds Move - Benzinga
Royal Bank of Canada Reaffirms Outperform Rating for Pyxis Oncology (NASDAQ:PYXS) - MarketBeat
Pyxis Oncology to Focus on PYX-201, Suspends PYX-106 Program - MarketWatch
Pyxis Oncology advances lead cancer drug PYX-201 - Investing.com
Pyxis Oncology to prioritize PYX-201, suspends investment in PYX-106 - TipRanks
Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201 - The Manila Times
Pyxis Oncology, Inc. Announces Portfolio Prioritization, Focusing Resources on Its Lead Clinical Program, PYX-201 - Marketscreener.com
Pyxis Oncology stock hits 52-week low at $1.5 amid market challenges - Investing.com Canada
Pyxis Oncology's SWOT analysis: ADC developer's stock shows promise amid trials - Investing.com Canada
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives $10.00 Average Price Target from Brokerages - MarketBeat
Pyxis Oncology stock hits 52-week low at $1.64 - Investing.com
Pyxis Oncology stock hits 52-week low at $1.64 By Investing.com - Investing.com UK
Jacobs Levy Equity Management Inc. Makes New Investment in Pyxis Oncology, Inc. (NASDAQ:PYXS) - MarketBeat
14,897 Shares in Pyxis Oncology, Inc. (NASDAQ:PYXS) Bought by Intech Investment Management LLC - Defense World
Pyxis Oncology: Speculative Buy Opportunity With Multiple Catalysts Ahead (NASDAQ:PYXS) - Seeking Alpha
CFO & COO of Pyxis Oncology Pamela Connealy Buys 13% More Shares - Yahoo Finance
Pyxis Oncology CFO acquires shares worth $174,364 - Investing.com India
Pyxis Oncology CFO acquires shares worth $174,364 By Investing.com - Investing.com South Africa
Institutional owners may ignore Pyxis Oncology, Inc.'s (NASDAQ:PYXS) recent US$142m market cap decline as longer-term profits stay in the green - Yahoo Finance
Pressure on Pyxis despite promising PYX-201 data - The Pharma Letter
Pyxis Oncology's SWOT analysis: ADC innovator's stock poised for growth - Investing.com
Pyxis Oncology's SWOT analysis: ADC innovator's stock poised for growth By Investing.com - Investing.com UK
Pyxis Oncology (NASDAQ:PYXS) Downgraded by William Blair to “Market Perform” - Defense World
Royal Bank of Canada Boosts Pyxis Oncology (NASDAQ:PYXS) Price Target to $10.00 - Defense World
Pyxis Oncology’s (PYXS) Buy Rating Reaffirmed at HC Wainwright - Defense World
William Blair Downgrades Pyxis Oncology (PYXS) - MSN
Pyxis stock craters 46% amid Phase 1 data, William Blair downgrade - MSN
Stock market news: Perspective Therapeutics -44.33%, Pyxis Oncology -42.93% among top losers during mid day trading - Business Upturn
Pyxis stock craters 46% amid Phase 1 data, William Blair downgrade (NASDAQ:PYXS) - Seeking Alpha
Stock market today: Pyxis Oncology plunges by 47.25% while Perspective Therapeutics declines by 46.68% in early trading - Business Upturn
Stock market today: SCWorx Corp. gains 141.81% while Pyxis Oncology down by 46.41% in early trading - Business Upturn
Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns - Benzinga
Pyxis Oncology (NASDAQ:PYXS) Rating Lowered to Market Perform at William Blair - MarketBeat
Pyxis Oncology (NASDAQ:PYXS) Earns Buy Rating from HC Wainwright - MarketBeat
PYXS shares target upgraded, outperform on positive trial data - Investing.com
Institutional investors in Pyxis Oncology, Inc. (NASDAQ:PYXS) lost 11% last week but have reaped the benefits of longer-term growth - Simply Wall St
Pyxis Oncology plummets 38% on preliminary phase 1 data for cancer asset - MSN
Pyxis Oncology Reports Promising Phase 1 Trial Results - TipRanks
Pyxis Oncology announces preliminary PYX-201 data, collaboration with Merck - TipRanks
Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data - The Manila Times
Pyxis Oncology, Inc. Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data - Marketscreener.com
Stephens & Co. Initiates Coverage of Pyxis Oncology (PYXS) with Overweight Recommendation - MSN
EPOCH 47: BIOTECH MARKET RESEARCH $PYXS - substack.com
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives $9.57 Consensus Target Price from Analysts - MarketBeat
Pyxis Oncology, Inc. (NASDAQ:PYXS) Short Interest Up 19.3% in October - MarketBeat
Pyxis Oncology FY2024 EPS Forecast Lowered by HC Wainwright - MarketBeat
Finanzdaten der Pyxis Oncology Inc-Aktie (PYXS)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):